Collaboration, License and Co-Promotion Agreements - Summary (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Collaboration, License and Co-Promotion Agreements
Total collaborative arrangements revenue	$ 66,106	$ 39,572	$ 186,498	$ 96,248
Allergan | Product related collaborative arrangements | North America | Linaclotide
Collaboration, License and Co-Promotion Agreements
Total collaborative arrangements revenue	60,285	35,083	160,294	84,790
Allergan | Product related collaborative arrangements | Europe | Linaclotide
Collaboration, License and Co-Promotion Agreements
Total collaborative arrangements revenue	110		300
Allergan | Co-Promotion Agreements | Viberzi
Collaboration, License and Co-Promotion Agreements
Total collaborative arrangements revenue	424		1,428
AstraZeneca | Product related collaborative arrangements | China, Hong Kong, and Macau | Linaclotide
Collaboration, License and Co-Promotion Agreements
Total collaborative arrangements revenue	77	474	371	2,170
Almirall | Product related collaborative arrangements | Europe | Linaclotide
Collaboration, License and Co-Promotion Agreements
Total collaborative arrangements revenue		143	3	360
Astellas | Collaborative arrangement
Collaboration, License and Co-Promotion Agreements
Total collaborative arrangements revenue	4,400	1,800	21,500	5,900
Astellas | Product related collaborative arrangements | Japan | Linaclotide
Collaboration, License and Co-Promotion Agreements
Total collaborative arrangements revenue	4,446	1,806	21,460	5,886
Exact Sciences Corp | Co-Promotion Agreements | Cologuard
Collaboration, License and Co-Promotion Agreements
Total collaborative arrangements revenue	$ 764	$ 2,066	$ 2,642	$ 3,042